Navigation Links
Potential treatments for neurofibromatosis

Neurofibromatosis can leave its patients miserable and debilitated with chronic itching or pain from disfiguring tumors. Infants affected by the disease face possible paralysis or damage to the brain and other organs.

The disease frustrates doctors because there's no effective treatment even though the responsible gene was identified more than a decade ago. Currently little can be done to treat a disease that affects more people than cystic fibrosis, hereditary muscular dystrophy, Huntington's disease and Tay Sachs combined.

Now, however, research by IU School of Medicine scientist D. Wade Clapp, M.D., and his colleagues David A. Ingram, Jr., M.D. and Feng-Chun Yang, M.D., Ph.D., have identified a promising target to treat the symptoms of neurofibromatosis. They hope to begin preliminary testing in humans by the end of this year, and are experimenting with potential drug compounds now.

Dr. Clapp, professor of pediatrics and of microbiology and immunology, said one target of their efforts will be mast cells, which are immune system cells that are involved in asthma and allergic reactions. Mast cells play a role in neurofibromatosis because they also are involved in blood vessel formation -- and tumors need blood vessels in order to grow.

"We are beginning to have a better understanding of cell to cell interactions that lead to the development of tumors and are poised to answer some of the most perplexing questions that underlie neurofibromatosis," said Dr. Clapp.

"Our work may well be applicable to other types of tumors such as breast and ovarian cancers, because inflammatory cells play an important role in tumor formation in these malignancies."

Neurofibromatosis results from mutations in a gene called NF 1. In humans, NF 1 mutations resulting in neurofibromatosis occur in one in 4,000 births, equally affecting both sexes and all races and ethnicities. It is the most common neurological disorder caused by a single gene. Some NF 1 mutations are inherited, but the NF1 gene is so large that many mutations occur spontaneously rather than being passed from parent to child.

Everyone has two copies of the NF 1 gene, which produces a protein called neurofibromin that controls cell division. If both NF 1 genes are defective, not enough neurofibromin is produced, cell division takes off and tumors develop.

"It's like an engine being driven at full speed," said Dr. Clapp.

To encourage development of the blood vessels they need, the tumors emit chemical signals that cause the mast cells to congregate in tissues surrounding the tumors. The mast cells create chemicals called growth factors that enable the creation of blood vessels.

The IU investigators now are identifying drugs that can disrupt the function of mast cells and their proteins in ways that they believe will starve the tumors.

"It's much easier to develop targets against a non-malignant cell than it is the malignant cell itself," said Dr. Clapp. That's because the biological activities of non-malignant cells are stable, while malignant cells are constantly changing due to the genetic instability common to tumors.

By using drugs that target the mast cells' ability to promote blood vessel growth, Clapp and his colleagues hope to prevent tumors from getting larger. Eventually, with continuing treatment, they hope the tumors will shrink or die from lack of blood vessel support.

Neurofibromatosis gets its name from neurofibromas, the disfiguring and often painful tumors that grow along nerve coverings and form on or under the skin. In most patients, the tumors begin to appear in adolescence or adulthood. A patient may develop hundreds of neurofibromas over a lifetime.

Some NF 1 patients also develop numerous light brown (café-au-lait) spots on the skin, enlargement and deformation of bones and curvature of the spine (scoliosis), and in many instances, learning disorders. Occ asionally, tumors may develop in the brain, on cranial nerves, or on the spinal cord.

However, a rare form of the disease occurs in infants and young children, with tumors growing on major nerves, such as the sciatic nerve that connects the spinal cord with the leg and foot muscles. The tumors can interfere with the function of the brain and other organs, or prevent patients from walking.

"Those are particularly tough problems. They're very challenging to treat surgically, and radiation and chemotherapy don't help," said Dr. Clapp.


'"/>

Source:News-Medical.Net


Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Potential vaccine developed for deadly leishmaniasis disease
6. Potential heart benefit found in stem cells
7. New understanding of DNA repair may pave way to cancer treatments
8. Researchers discover stem cell guide that may be key for targeting neural stem cell treatments
9. Access to existing medical treatments could save more lives than spending to improve the treatments
10. DNA end caps may lead to cancer treatments, UT Southwestern researchers report
11. New understanding of parasite cell structures may provide treatments for serious tropical diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority on the ... Charles W. Stellar has been named by the WEDI Board of Directors as WEDI’s ... an executive leader with more than 35 years of experience in healthcare, association management ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... 23, 2016 Oxitec CEO Hadyn ... at 10:15 a.m. ET before the United States House Committee ... mosquitos can play in controlling the spread of the ... virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) ... a self-limiting gene. Trials in Brazil , ...
(Date:5/20/2016)... Diego, CA (PRWEB) , ... May 20, 2016 , ... ... that 10 of its most experienced veterinary clients have treated over 100 of their ... cutting edge technology to provide the highest level of care for their patients. ...
Breaking Biology Technology: